LEON: LION bioscience AG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : LEON: LION bioscience AG

LEON 0.0127

0.0%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (34)	1/17/2003 5:20:34 AM
From: nigel bates	of 36

CAMBRIDGE, Mass. & HEIDELBERG, Germany--(BUSINESS WIRE)--Jan. 17, 2003--LION bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON), a leading provider of integrated IT solutions for the life science industry, announced it has signed a global licensing agreement with leading pharmaceutical company Eli Lilly and Company for SRS integration technology modules aimed at better drug discovery. "We are delighted to provide our unique SRS suite of integration technology and expertise to Lilly and look forward to a strong, long-term working relationship," said LION bioscience Chief Business Officer Dr. Daniel Keesman. "The SRS suite continues to strengthen its position in the industry as the leading data integration software and we are confident it will add value to Lilly's research efforts."...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next